United Therapeutics Co. (NASDAQ:UTHR) Director Sells $9,781,722.98 in Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the transaction, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Price Performance

NASDAQ UTHR opened at $360.16 on Friday. The company has a market cap of $16.08 billion, a P/E ratio of 15.82, a P/E/G ratio of 1.05 and a beta of 0.54. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The stock has a 50-day moving average of $371.01 and a two-hundred day moving average of $344.37.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million for the quarter, compared to the consensus estimate of $722.62 million. During the same period in the prior year, the firm earned $5.38 EPS. The firm’s revenue for the quarter was up 22.9% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. HC Wainwright increased their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Finally, The Goldman Sachs Group raised their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $370.86.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. ClariVest Asset Management LLC boosted its stake in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares during the period. Innealta Capital LLC purchased a new stake in shares of United Therapeutics during the second quarter worth approximately $33,000. USA Financial Formulas acquired a new stake in United Therapeutics in the third quarter valued at approximately $33,000. Brooklyn Investment Group purchased a new position in United Therapeutics in the third quarter worth approximately $33,000. Finally, Capital Performance Advisors LLP acquired a new stake in United Therapeutics in the third quarter valued at $82,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.